Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.41 |
| ▸ | DRD3 | P35462 | 9/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084254 | 0.83 | DPP4 (0.43) | DRD2DRD3HTR1DMTNR1B | |
| SCHEMBL4084257 | 0.80 | MTNR1B (0.50) | MTNR1B | |
| SCHEMBL4082356 | 0.78 | DPP4 (0.42) | DRD2DRD3HTR1DMTNR1B | |
| SCHEMBL28145466 | 0.76 | ESR1 (0.51) | DRD2DRD3ACEESR1ESR2 | |
| SCHEMBL2121244 | 0.75 | ESR1 (0.40) | DRD2DRD3HTR1DESR1ESR2 | |
| SCHEMBL22777003 | 0.75 | TRPV1 (0.49) | DRD2DRD3HTR1DESR1ESR2 | |
| SCHEMBL2082119 | 0.75 | GHSR (0.49) | DRD2DRD3HTR1D | |
| SCHEMBL30920111 | 0.75 | GHSR (0.49) | DRD2DRD3HTR1D | |
| SCHEMBL7974143 | 0.74 | ESR1 (0.51) | DRD2DRD3ESR1ESR2 | |
| SCHEMBL4082358 | 0.74 | MTNR1B (0.49) | DRD2DRD3HTR1DMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113666863-B | Biaryl compounds useful as rory modulators | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-113773251-B | Anilines useful as rory modulators | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |